AnaptysBio, Inc. (ANAB)
| Market Cap | 705.98M |
| Revenue (ttm) | 24.09M |
| Net Income (ttm) | -108.01M |
| Shares Out | 28.24M |
| EPS (ttm) | -2.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 362,197 |
| Open | 24.00 |
| Previous Close | 23.87 |
| Day's Range | 23.74 - 25.47 |
| 52-Week Range | 18.20 - 37.89 |
| Beta | 0.15 |
| Analysts | Buy |
| Price Target | 36.92 (+47.7%) |
| Earnings Date | Aug 8, 2022 |
About ANAB
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable t... [Read more...]
Financial Performance
In 2021, AnaptysBio's revenue was $63.18 million, a decrease of -15.77% compared to the previous year's $75.00 million. Losses were -$57.80 million, 190.0% more than in 2020.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for ANAB stock is "Buy." The 12-month stock price forecast is 36.92, which is an increase of 47.68% from the latest price.
News
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Lags Revenue Estimates
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -21.05% and 80.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating re...
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference
SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Fa...
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms ap...
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Lags Revenue Estimates
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -50.57% and 87.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update
SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms app...
AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune con...
AnaptysBio, Inc. (ANAB) Soars 6.2%: Is Further Upside Left in the Stock?
AnaptysBio, Inc. (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer
SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune con...
AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal
AnaptysBio's (ANAB) phase II study evaluating imsidolimab for treating moderate-to-severe acne, fails to show improvement over placebo in top-line primary or secondary endpoints. Shares down.
AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne
AnaptysBio Inc's (NASDAQ: ANAB) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acne did not demonstrate efficacy over placebo on primary or secondary endpoints. Imsidolimab was generally safe...
AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne
SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune con...
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -149.56% and 99.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune co...
AnaptysBio, Inc. (ANAB) Earnings Expected to Grow: What to Know Ahead of Q4 Release
AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune cont...
AnaptysBio Announces Appointment of Daniel Faga to Board of Directors
SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune cont...
AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune cont...
AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune cont...
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 67.57% and 150.54%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates
SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune con...
AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard
SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune cont...
AnaptysBio Reveals Updated Imsidolimab Data In Severe Form Of Psoriasis
AnaptysBio Inc (NASDAQ: ANAB) has announced updated data from the GALLOP Phase 2 trial of imsidolimab in generalized pustular psoriasis (GPP). GPP is a rare and extreme form of psoriasis characterized b...
AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis
SAN DIEGO, Oct. 02, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune cont...
AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune con...